Catherine Owen Adams

Stories

Acadia pushes Alzheimer's psychosis drug to phase 3 despite missed trial goal

As of September 2026: Advancing remlifanserin to phase 3

Acadia Pharmaceuticals said its experimental Alzheimer's psychosis treatment missed the primary goal of a phase 2 trial. The company is advancing remlifanserin to phase 3 anyway, betting a refined study design can turn a near-miss into a win.

Updated Sep 24

Notable Quotes

With the high unmet medical need in this population, the efficacy that we've seen so far ... as well as the safety and tolerability profile, this molecule offers the potential for patients with Alzheimer's disease psychosis, and it is absolutely worth our investment to move this forward into the phase 3 trial.

from Acadia pushes Alzheimer's psychosis drug to phase 3 despite missed trial goal · Updated Sep 24

We are looking into how to enrich the population for further enhancement through phase 3.

from Acadia pushes Alzheimer's psychosis drug to phase 3 despite missed trial goal · Updated Sep 24